Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.02
ACT's Cash to Debt is ranked lower than
55% of the 921 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. ACT: 0.02 )
ACT' s 10-Year Cash to Debt Range
Min: 0.02   Max: 32.29
Current: 0.02

0.02
32.29
Equity to Asset 0.54
ACT's Equity to Asset is ranked higher than
64% of the 842 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. ACT: 0.54 )
ACT' s 10-Year Equity to Asset Range
Min: 0.27   Max: 0.9
Current: 0.54

0.27
0.9
F-Score: 5
Z-Score: 2.30
M-Score: -2.24
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) -9.71
ACT's Operating margin (%) is ranked higher than
57% of the 870 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.37 vs. ACT: -9.71 )
ACT' s 10-Year Operating margin (%) Range
Min: -21.33   Max: 37.1
Current: -9.71

-21.33
37.1
Net-margin (%) -12.48
ACT's Net-margin (%) is ranked higher than
56% of the 870 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.90 vs. ACT: -12.48 )
ACT' s 10-Year Net-margin (%) Range
Min: -22.48   Max: 35.15
Current: -12.48

-22.48
35.15
ROE (%) -9.45
ACT's ROE (%) is ranked higher than
58% of the 894 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.44 vs. ACT: -9.45 )
ACT' s 10-Year ROE (%) Range
Min: -23.54   Max: 22.08
Current: -9.45

-23.54
22.08
ROA (%) -4.61
ACT's ROA (%) is ranked higher than
59% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.27 vs. ACT: -4.61 )
ACT' s 10-Year ROA (%) Range
Min: -13.02   Max: 19.77
Current: -4.61

-13.02
19.77
ROC (Joel Greenblatt) (%) -38.64
ACT's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.08 vs. ACT: -38.64 )
ACT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -39.46   Max: 93.56
Current: -38.64

-39.46
93.56
Revenue Growth (3Y)(%) 17.90
ACT's Revenue Growth (3Y)(%) is ranked higher than
87% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.30 vs. ACT: 17.90 )
ACT' s 10-Year Revenue Growth (3Y)(%) Range
Min: 6.4   Max: 36.8
Current: 17.9

6.4
36.8
EBITDA Growth (3Y)(%) -3.70
ACT's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. ACT: -3.70 )
ACT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -3.7   Max: 49.9
Current: -3.7

-3.7
49.9
» ACT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ACT Guru Trades in Q1 2014

Steve Mandel 2,378,308 sh (New)
Louis Moore Bacon 5,003 sh (New)
Ken Heebner 630,000 sh (New)
Leon Cooperman 264,093 sh (New)
John Paulson 300,000 sh (New)
Daniel Loeb 2,500,000 sh (New)
Joel Greenblatt 10,597 sh (New)
Paul Tudor Jones 53,200 sh (+3029.41%)
Vanguard Health Care Fund 3,647,500 sh (+269.93%)
Jim Simons 401,936 sh (+103.38%)
Jana Partners 901,888 sh (+81.50%)
Steven Cohen 83,190 sh (+47.20%)
George Soros 35,000 sh (+40.00%)
John Griffin 1,735,000 sh (+32.44%)
Private Capital 174,960 sh (+1.16%)
Eric Mindich 500,000 sh (unchged)
Francis Chou 35,400 sh (unchged)
RS Investment Management 939,682 sh (-11.22%)
Scott Black 67,883 sh (-16.26%)
Mario Gabelli 31,363 sh (-20.34%)
Pioneer Investments 620,874 sh (-22.97%)
Andreas Halvorsen 1,091,544 sh (-62.77%)
Diamond Hill Capital 18,613 sh (-80.00%)
Jeremy Grantham 1,306 sh (-92.86%)
Bill Nygren -693,000 sh (-9999.00%)
» More
Q2 2014

ACT Guru Trades in Q2 2014

Jean-Marie Eveillard 706,833 sh (New)
Kyle Bass 14,800 sh (New)
Bill Nygren 0 sh (+9999.00%)
Louis Moore Bacon 47,348 sh (+846.39%)
Jana Partners 2,654,328 sh (+194.31%)
Leon Cooperman 619,919 sh (+134.74%)
Paul Tudor Jones 101,500 sh (+90.79%)
George Soros 63,831 sh (+82.37%)
Eric Mindich 692,000 sh (+38.40%)
Jim Simons 507,725 sh (+26.32%)
Mario Gabelli 36,165 sh (+15.31%)
Andreas Halvorsen 1,207,824 sh (+10.65%)
Steve Mandel 2,478,628 sh (+4.22%)
John Paulson 300,000 sh (unchged)
Daniel Loeb 2,500,000 sh (unchged)
Steven Cohen 25,000 sh (unchged)
John Griffin 1,735,000 sh (unchged)
Jeremy Grantham Sold Out
Francis Chou Sold Out
Joel Greenblatt Sold Out
Diamond Hill Capital Sold Out
Private Capital 172,284 sh (-1.53%)
Vanguard Health Care Fund 3,359,667 sh (-7.89%)
RS Investment Management 845,397 sh (-10.03%)
Scott Black 48,858 sh (-28.03%)
Ken Heebner 370,000 sh (-41.27%)
Pioneer Investments 256,641 sh (-58.66%)
» More
Q3 2014

ACT Guru Trades in Q3 2014

Bernard Horn 20,689 sh (New)
Joel Greenblatt 8,180 sh (New)
Dodge & Cox 4,025 sh (New)
Larry Robbins 1,717,858 sh (New)
Steven Cohen 102,900 sh (+311.60%)
John Paulson 1,062,200 sh (+254.07%)
Vanguard Health Care Fund 8,555,596 sh (+154.66%)
George Soros 149,885 sh (+134.82%)
Andreas Halvorsen 2,550,336 sh (+111.15%)
Mario Gabelli 58,056 sh (+60.53%)
Eric Mindich 859,000 sh (+24.13%)
Daniel Loeb 2,875,000 sh (+15.00%)
Leon Cooperman 706,472 sh (+13.96%)
Jean-Marie Eveillard 740,675 sh (+4.79%)
Steve Mandel 2,478,628 sh (unchged)
John Griffin 1,735,000 sh (unchged)
Pioneer Investments 139,359 sh (unchged)
Kyle Bass Sold Out
Ken Heebner Sold Out
Paul Tudor Jones 101,193 sh (-0.30%)
Private Capital 167,468 sh (-2.80%)
Jana Partners 2,514,701 sh (-5.26%)
Scott Black 45,177 sh (-7.53%)
RS Investment Management 550,630 sh (-34.87%)
Louis Moore Bacon 28,636 sh (-39.52%)
Jim Simons 128,162 sh (-74.76%)
» More
Q4 2014

ACT Guru Trades in Q4 2014

Diamond Hill Capital 2,966 sh (New)
Jim Simons 454,162 sh (+254.37%)
George Soros 321,214 sh (+114.31%)
Andreas Halvorsen 4,585,892 sh (+79.82%)
Jean-Marie Eveillard 1,176,582 sh (+58.85%)
John Paulson 1,560,601 sh (+46.92%)
Leon Cooperman 943,572 sh (+33.56%)
Daniel Loeb 3,450,000 sh (+20.00%)
Larry Robbins 1,841,869 sh (+7.22%)
Vanguard Health Care Fund 8,795,896 sh (+2.81%)
Jean-Marie Eveillard 60 sh (unchged)
Bernard Horn 20,689 sh (unchged)
Joel Greenblatt Sold Out
Steve Mandel Sold Out
Private Capital 166,197 sh (-0.76%)
John Griffin 1,625,000 sh (-6.34%)
Scott Black 41,091 sh (-9.04%)
Dodge & Cox 3,293 sh (-18.19%)
RS Investment Management 414,013 sh (-24.81%)
Pioneer Investments 96,064 sh (-31.07%)
Jana Partners 1,718,804 sh (-31.65%)
Mario Gabelli 26,890 sh (-53.68%)
Eric Mindich 332,850 sh (-61.25%)
Louis Moore Bacon 7,666 sh (-73.23%)
Paul Tudor Jones 2,700 sh (-97.33%)
Steven Cohen 1,500 sh (-98.54%)
» More
» Details

Insider Trades

Latest Guru Trades with ACT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Actavis PLC

SymbolPriceYieldDescription
ACTPRA0.000.00- 5 1/2 % Cum.Conv.Pref.Shs 2015-1.3.18 Series -A-

Guru Investment Theses on Actavis PLC

Vanguard Health Care Fund Comments on Actavis PLC - Mar 27, 2015

Actavis (ACT) is a specialty pharmaceutical company that develops generic and branded products. We owned Actavis prior to its Forest Labs acquisition but increased our position. We are attracted to the uniqueness of the combined company’s business model, which provides exposure to both generic and branded pharmaceuticals globally. The company’s Irish tax rate could also be strategically important in future mergers and acquisitions. Actavis was the fund’s second-largest holding as of the end of the period.



From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report.



Check out Vanguard Health Care Fund latest stock trades

Bernard Horn Comments on Actavis PLC - Oct 30, 2014

On July 1, Actavis (ACT) announced the completion of its acquisition of Forest Laboratories Inc. (a Fund holding), in a cash and equity transaction valued at approximately $28 billion. We maintained a position in Actavis, as its pro-forma financial statements fit the Polaris valuation profile. As one of the largest generic pharmaceutical companies, Actavis is expected to broaden its product platform with the Forest acquisition, increase operating cash flow and realize $1 billion in cost synergies.

From Bernard Horn (Trades, Portfolio)’s Polaris Global Value Fund Q3 2014 Shareholder Letter.

Check out Bernard Horn latest stock trades

Diamond Hill Capital Comments on Actavis PLC - Jul 25, 2014

We eliminated our position in specialty pharmaceutical company Actavis PLC (ACT) as the price to intrinsic value relationship narrowed. We originally received shares when Actavis bought portfolio holding Warner Chilcott.

From Diamond Hill Capital (Trades, Portfolio)'s Small Cap Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Actavis Inc - Jun 26, 2014

Pharmaceutical company Actavis, Inc. PLC (ACT) announced the acquisition of drug manufacturer Forest Laboratories, Inc. during the quarter for a combination of cash and stock. Investors viewed this as a positive for Actavis due to expected synergies and an increase in the branded drug business as a percent of revenues.



From Diamond Hill Capital's Small Cap Fund Commentary – First Quarter 2014.



Check out Diamond Hill Capital latest stock trades

Francis Chou Comments on Actavis Inc. - Sep 05, 2013

Another big winner was Actavis Inc. (ACT), formerly Watson Pharmaceutical. We first purchased Actavis in 2006 at $25. We kept buying the shares in 2007, and on June 30, 2013, it was priced at $126.22. It shows that when you are accurate in your estimation of intrinsic value and buy them at a significant discount, add in good management and respectable growth in intrinsic value, the investment works out really well. This is true even if you bought them when the market indices were trading at an all-time high. "Value traps" generally occur when you are wrong in your estimation of intrinsic value, pay too much and the company's intrinsic value is static and/or decreasing in value.

From Francis Chou's semi-annual report 2013.

Check out Francis Chou latest stock trades

Top Ranked Articles about Actavis PLC

Vanguard Health Care Fund Comments on Actavis PLC
Actavis (ACT) is a specialty pharmaceutical company that develops generic and branded products. We owned Actavis prior to its Forest Labs acquisition but increased our position. We are attracted to the uniqueness of the combined company’s business model, which provides exposure to both generic and branded pharmaceuticals globally. The company’s Irish tax rate could also be strategically important in future mergers and acquisitions. Actavis was the fund’s second-largest holding as of the end of the period. Read more...
Bernard Horn's Most Heavily Weighted Stocks
Bernard Horn (Trades, Portfolio) of Polaris Global Value Fund currently owns 89 stocks, valued at $275 million, with a quarter over quarter turnover of 4%. Read more...
Dodge & Cox's Top New Buys of Q3
The Dodge & Cox fund in companies that it believes the stock market is undervaluing but have strong potential long-term growth. It returned 8% for the first nine months of the year, just shy of the 8.3% return of the S&P 500. Read more...
A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio
Over the duration of the third quarter the Vanguard Health Care Fund added two new stocks to its holdings. The fund now holds on to 89 stocks valued at $39.18 billion. The following companies are Vanguard's top portfolio holdings. Read more...
Bernard Horn's Polaris Global Fund Buys 4 New Stocks
Bernard Horn (Trades, Portfolio) operates the Maine-based, strict value Polaris Global Value Fund (PGVFX). After a prosperous 2013, Horn predicted single-digit returns for stocks in 2014, which has proved accurate through the first three quarters. He still sees plenty of opportunity around the world, however, writing in his third quarter investor letter: Read more...
Bernard Horn Comments on Actavis PLC
On July 1, Actavis (ACT) announced the completion of its acquisition of Forest Laboratories Inc. (a Fund holding), in a cash and equity transaction valued at approximately $28 billion. We maintained a position in Actavis, as its pro-forma financial statements fit the Polaris valuation profile. As one of the largest generic pharmaceutical companies, Actavis is expected to broaden its product platform with the Forest acquisition, increase operating cash flow and realize $1 billion in cost synergies. Read more...
Diamond Hill Capital Comments on Actavis PLC
We eliminated our position in specialty pharmaceutical company Actavis PLC (ACT) as the price to intrinsic value relationship narrowed. We originally received shares when Actavis bought portfolio holding Warner Chilcott. Read more...
Diamond Hill Capital Comments on Actavis Inc
Pharmaceutical company Actavis, Inc. PLC (ACT) announced the acquisition of drug manufacturer Forest Laboratories, Inc. during the quarter for a combination of cash and stock. Investors viewed this as a positive for Actavis due to expected synergies and an increase in the branded drug business as a percent of revenues. Read more...
Top 5 Hedge Fund Net Buys
The recent top net buys of the hedge fund gurus were American Airlines (AAL), Actavis (ACT), Allegion (ALLE), Gilead Sciences (GILD), and Verizon (VZ). I found the net buys by using the S&P 500 Grid at GuruFocus. I adjusted the setting to include only hedge fund gurus and examined the results for both S&P 500 companies and non-S&P 500 companies. Read more...

Ratios

vs
industry
vs
history
Forward P/E 14.49
ACT's Forward P/E is ranked higher than
91% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 67.57 vs. ACT: 14.49 )
N/A
P/B 3.00
ACT's P/B is ranked higher than
71% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.76 vs. ACT: 3.00 )
ACT' s 10-Year P/B Range
Min: 1.08   Max: 5.9
Current: 3

1.08
5.9
P/S 5.10
ACT's P/S is ranked higher than
53% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.26 vs. ACT: 5.10 )
ACT' s 10-Year P/S Range
Min: 0.99   Max: 5.3
Current: 5.1

0.99
5.3
PFCF 33.50
ACT's PFCF is ranked higher than
85% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 639.25 vs. ACT: 33.50 )
ACT' s 10-Year PFCF Range
Min: 6.64   Max: 263.71
Current: 33.5

6.64
263.71
POCF 30.99
ACT's POCF is ranked higher than
79% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 37.05 vs. ACT: 30.99 )
ACT' s 10-Year POCF Range
Min: 5.97   Max: 30.73
Current: 30.99

5.97
30.73
EV-to-EBIT -78.11
ACT's EV-to-EBIT is ranked higher than
63% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.20 vs. ACT: -78.11 )
ACT' s 10-Year EV-to-EBIT Range
Min: -264.2   Max: 145.1
Current: -78.11

-264.2
145.1
Current Ratio 1.37
ACT's Current Ratio is ranked higher than
57% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. ACT: 1.37 )
ACT' s 10-Year Current Ratio Range
Min: 1.35   Max: 9.8
Current: 1.37

1.35
9.8
Quick Ratio 0.96
ACT's Quick Ratio is ranked higher than
57% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. ACT: 0.96 )
ACT' s 10-Year Quick Ratio Range
Min: 0.8   Max: 8.82
Current: 0.96

0.8
8.82
Days Inventory 114.05
ACT's Days Inventory is ranked higher than
79% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.81 vs. ACT: 114.05 )
ACT' s 10-Year Days Inventory Range
Min: 107.12   Max: 216.83
Current: 114.05

107.12
216.83
Days Sales Outstanding 66.29
ACT's Days Sales Outstanding is ranked higher than
78% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 78.61 vs. ACT: 66.29 )
ACT' s 10-Year Days Sales Outstanding Range
Min: 38.55   Max: 103.03
Current: 66.29

38.55
103.03

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 2.40
ACT's Price/DCF (Projected) is ranked higher than
84% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.40 vs. ACT: 2.40 )
ACT' s 10-Year Price/DCF (Projected) Range
Min: 0.61   Max: 2.96
Current: 2.4

0.61
2.96
Price/Median PS Value 2.80
ACT's Price/Median PS Value is ranked higher than
52% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. ACT: 2.80 )
ACT' s 10-Year Price/Median PS Value Range
Min: 0.67   Max: 5.17
Current: 2.8

0.67
5.17
Earnings Yield (Greenblatt) -1.30
ACT's Earnings Yield (Greenblatt) is ranked higher than
57% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. ACT: -1.30 )
ACT' s 10-Year Earnings Yield (Greenblatt) Range
Min: -1.3   Max: 11.4
Current: -1.3

-1.3
11.4
Forward Rate of Return (Yacktman) 9.97
ACT's Forward Rate of Return (Yacktman) is ranked higher than
78% of the 520 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.39 vs. ACT: 9.97 )
ACT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2.1   Max: 16.5
Current: 9.97

-2.1
16.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:A60.Germany,
Actavis plc, formerly known as Actavis Limited was incorporated in Ireland on May 16, 2013. It is a integrated specialty pharmaceutical company engaged in development, manufacturing, marketing, sale and distribution of generic, branded generic, brand name, biosimilar and over-the-counter pharmaceutical products. It also develop and out-license generic pharmaceutical products mainly in Europe through its Medis third-party business. The operates in three segments, Actavis Pharma, Actavis Specialty Brands and Anda Distribution. The Actavis Pharma segment includes off-patent pharmaceutical products that are therapeutically equivalent to proprietary products. The Actavis Specialty Brands segment includes patent-protected products and certain trademarked off-patent products that the Company sells and markets as brand pharmaceutical products. The Anda Distribution segment distributes generic and brand pharmaceutical products manufactured by third parties, as well as by the Company, primarily to independent pharmacies, pharmacy chains, pharmacy buying groups and physicians' offices. It is subject to extensive, complex and evolving regulation by the federal government, principally the FDA, and to a lesser extent, by the U.S. Drug Enforcement Administration Occupational Safety and Health Administration and state government agencies, as well as by various regulatory agencies in foreign countries where its products or product candidates are being manufactured and/or marketed. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other federal statutes and regulations govern or influence the testing, manufacturing, packing, labeling, storing, record keeping, safety, approval, advertising, promotion, sale and distribution of its products.
» More Articles for ACT

Headlines

Articles On GuruFocus.com
Vanguard Health Care Fund Comments on Actavis PLC Mar 27 2015 
Vanguard Health Care Fund 2014 Annual Report Mar 27 2015 
Pershing Square Holdings: First Annual Report Mar 25 2015 
Ruane, Cunniff & Goldfarb Inc Comments on Valeant Mar 16 2015 
Bernard Horn's Most Heavily Weighted Stocks Mar 06 2015 
Endo International Shares Upbeat After Positive Q4 Earnings Report Mar 03 2015 
AstraZeneca’s Q4 Misses Profit Estimates, But Management Stays Upbeat Feb 13 2015 
A Look at Leon Cooperman's Most Performing Recent Buys Jan 30 2015 
Pharmaceuticals Sector To See High Voltage Action in 2015 Jan 23 2015 
The Gurus to Follow Based on Sector — Part 2 Dec 09 2014 


More From Other Websites
ACTAVIS PLC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Mar 27 2015
Which 4 Big Drugmakers Have Rising Estimates? Mar 27 2015
Should You Be Concerned About Billionaire Leon Cooperman’s Top Holdings? Mar 26 2015
A look at Leon Cooperman, subject of SEC inquiry Mar 26 2015
EMD Finance’s Yankee Corporate Issue Is the Largest in 2015 Mar 26 2015
Highlights of Blue Ridge Capital’s 4Q14 Holdings Mar 26 2015
Farallon Capital Adds a New Position in CareFusion Corporation Mar 26 2015
With New Valeant Pharmaceuticals Intl Inc (VRX) Stake, Bill Ackman Maintains Large Exposure to... Mar 26 2015
Is a Para IV Filing Rewarding for a Generic Company? Mar 25 2015
Regulations Are Instrumental in the Marketing Authorization Process Mar 25 2015
Why Is the Generics Industry Controlled by Regulations? Mar 25 2015
Bargaining Power Is in the Hands of the Distribution Industry Mar 25 2015
4 Top-Ranked Health Care ETFs for a Healthy Portfolio - ETF News And Commentary Mar 25 2015
Zacks Rank #1 Additions for Wednesday - Tale of the Tape Mar 25 2015
Talking Allergan at Tulane: a 'Horse Choker,' the 'Shamarendum' and More Mar 24 2015
Will pharma rally continue? Mar 24 2015
Generics Are Climbing up the Value Chain Mar 23 2015
The Federal Reserve: Patient No More? Mar 23 2015
US bond market buckles after surge Mar 23 2015
What Two Factors Are Driving the US Generics Market? Mar 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK